Stanford researcher writes that readers should check the effect size of results instead of looking at the p-value.
Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.
A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.
An issue of Lancet Psychiatry is devoted to clarifying the lack of efficacy for Zoloft (sertraline).
Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.
Current standards for clinical trials rely on statistical methods that allow for ineffective treatments to gain approval.
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
The candidate-gene approach to depression goes unsupported and is likely based on bad science, new research finds.
John Ioannidis, a leading expert on research methods, takes a critical look at the way professional societies write treatment guidelines.
An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.
A new study demonstrates how the choice of statistical techniques when examining data plays a large role in scientific outcomes.
New research suggests that clinicians should exercise caution prescribing SNRIs as first-line treatment for mood and anxiety disorders.
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.
A new study finds that sponsors of clinical trials in the EU continue to fail at reporting their results as required by recent legislation.
Reanalysis of the original primary outcome measure in the STAR*D study suggests STAR*D findings inflate improvement on antidepressant medication and exclusion criteria in conventional clinical trials results in overestimation of antidepressant efficacy.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Researchers report the cumulative effects of major biases on the apparent efficacy of antidepressant and psychotherapy treatments.
A new study claims that quantitative research in psychology is “worryingly imprecise” and that generalizations may be flawed and misleading.
Study details Medicaid-insured birth cohort’s exposure to psychiatric medications and mental health services.
Review of pediatric antidepressant studies finds the vast majority are negative on primary outcomes and an increased risk for suicidality.
A new study, published online by the Open Science Foundation, suggests that questionable research practices (QRPs) are prevalent in the fields of ecology and evolution.
A new study published in Frontiers in Psychiatry concludes that “antidepressants are largely ineffective and potentially harmful.”
From Pacific Standard: The U.S. government has never penalized anyone for breaking a law that requires institutions to report the results of clinical trials. A...
Due to the thickness of the scalp and skull, transcranial electrical stimulation (TES) is incapable of targeting networks of neurons in the brain.